CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsAltman Z-Score 5.79: safe zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
3.16%Above 5Y avg (2.08%)
Annual Rate
CNY 0.60Paid semi-annual
Payout Ratio
58.1%Sustainable
Payback Period
38.9 yr
Last Ex-Dividend
May 29, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.33BCNY643.33M · vs all stocks (USD)
Trailing P/E
26.89xvs Biotechnology peers
Revenue (TTM)
1.55BCNY230.31M · vs all stocks (USD)
Profit Margin
10.46%vs Biotechnology peers
Beta
-0.1710xvs all stocks
52-Week Change
-36.86%vs all stocks
Forward Annual Dividend Yield
3.16%vs all stocks
Market Capitalization
4.33BCNY643.33M · vs all stocks (USD)
Enterprise Value
4.11BCNY609.71M · vs all stocks (USD)
Trailing P/E
26.89xvs Biotechnology peers
Forward P/E
11.86xvs Biotechnology peers
Price to Sales (TTM)
2.85xvs Biotechnology peers
Price to Book (MRQ)
2.40xvs Biotechnology peers
Enterprise to Revenue
2.65xvs Biotechnology peers
Enterprise to EBITDA
18.78xvs Biotechnology peers
Gross Margin
65.86%vs Biotechnology peers
Profit Margin
10.46%vs Biotechnology peers
Operating Margin
11.56%vs Biotechnology peers
Return on Assets (TTM)
3.16%vs Biotechnology peers
Return on Equity (TTM)
8.10%vs Biotechnology peers
Revenue (TTM)
1.55BCNY230.31M · vs all stocks (USD)
Revenue per Share (TTM)
6.86CNYUpdated Aug 20, 2026Quarterly Revenue Growth
-0.90%vs Biotechnology peers
Gross Profit (TTM)
998.60MCNY148.31M · vs all stocks (USD)
EBITDA (TTM)
200.76MCNY29.82M · vs all stocks (USD)
Net Income (TTM)
162.24MCNY24.10M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-7.70%vs Biotechnology peers
Operating Cash Flow (TTM)
240.49MCNY35.72M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
39.93MCNY5.93M · vs all stocks (USD)
Forward Annual Dividend Rate
0.6000CNYUpdated Aug 20, 2026Forward Annual Dividend Yield
3.16%vs all stocks
Trailing Annual Dividend Rate
0.4667CNYUpdated Aug 20, 2026Trailing Annual Dividend Yield
2.46%vs all stocks
5-Year Average Dividend Yield
2.08%vs all stocks
Payout Ratio
58.14%vs Biotechnology peers
Minority Interest (Equity)
142.69MCNYFY2025 · Dec 31, 2025Revenue
1.55BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
550.81MCNYFY2025 · Dec 31, 2025Gross Profit
1.00BCNYFY2025 · Dec 31, 2025Operating Income
166.30MCNY24.70M · vs all stocks (USD)
Pre-tax Income
181.80MCNYFY2025 · Dec 31, 2025Income Tax Expense
18.24MCNYFY2025 · Dec 31, 2025Net Income
163.55MCNYFY2025 · Dec 31, 2025EBIT
184.14MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
285.94MCNYFY2025 · Dec 31, 2025Research & Development
110.78MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
590.06MCNYFY2025 · Dec 31, 2025Other Operating Expenses
24.86MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
1.89MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
2.34MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.7250CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.7250CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
227.86MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
227.86MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
163.55MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
1.64MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
144.46MCNYFY2025 · Dec 31, 2025Free Cash Flow
34.01MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
413.89MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
163.55MCNYFY2025 · Dec 31, 2025Other Non-cash Items
5.17MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-26.74MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
2.48MCNYFY2025 · Dec 31, 2025Capital Expenditures
-110.45MCNYFY2025 · Dec 31, 2025Purchase of Investments
-911.86MCNYFY2025 · Dec 31, 2025Sale of Investments
963.31MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-59.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-166.16MCNYFY2025 · Dec 31, 2025Other Financing Charges
-13.46MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-179.63MCNYFY2025 · Dec 31, 2025Shares Outstanding
228.22MSharesUpdated Aug 20, 2026Float Shares
90.27MSharesUpdated Aug 20, 2026% Held by Insiders
64.75%vs all stocks
% Held by Institutions
0.67%vs all stocks
Total Cash (MRQ)
485.59MCNY72.12M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.13CNYUpdated Aug 20, 2026Total Debt (MRQ)
73.20MCNY10.87M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0368xvs Biotechnology peers
Current Ratio (MRQ)
2.28xvs Biotechnology peers
Book Value per Share (MRQ)
8.08CNYUpdated Aug 20, 2026Total Assets
2.59BCNY384.05M · vs all stocks (USD)
Total Current Assets
1.18BCNYFY2025 · Dec 31, 2025Total Liabilities
634.19MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.41BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
113.61MCNYFY2025 · Dec 31, 2025Total Current Liabilities
520.58MCNYFY2025 · Dec 31, 2025Cash
413.87MCNYFY2025 · Dec 31, 2025Cash Equivalents
21.64KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
413.89MCNYFY2025 · Dec 31, 2025Other Short-term Investments
40.27MCNYFY2025 · Dec 31, 2025Accounts Receivable
452.44MCNYFY2025 · Dec 31, 2025Inventory
204.50MCNYFY2025 · Dec 31, 2025Accounts Payable
349.46MCNYFY2025 · Dec 31, 2025Short-term Debt
2.54MCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.39MCNYFY2025 · Dec 31, 2025Long-term Debt
61.36MCNYFY2025 · Dec 31, 2025Common Stock (Book)
190.18MCNYFY2025 · Dec 31, 2025Retained Earnings
1.01BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.95BCNY289.86M · vs all stocks (USD)
52-Week Low
14.20CNYUpdated Aug 20, 202652-Week High
34.56CNYUpdated Aug 20, 202652-Week Change
-36.86%vs all stocks
Beta
-0.1710xvs all stocks
50-Day MA
17.00CNYUpdated Aug 20, 2026200-Day MA
19.95CNYUpdated Aug 20, 2026Avg 10-Day Volume
15.59MSharesUpdated Aug 20, 2026Avg 30-Day Volume
17.76MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
0.7200CNYUpdated Aug 20, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Retained Earnings Heavy With Elevated Payout
Profits kept in the business fund much of what it owns, and it now pays out most of what it earns.
Reads
How does this company use capital?
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 5.79: safe zoneNotable
Altman Z-Score: 5.79
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Shenzhen Neptunus Bioengineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
476830
Tier 1ProductionApproval-Gated PipelineRule
Lionco Pharmaceutical Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
MiMedx Group, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tactile Systems Technology Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Ironwood Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jianmin Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Gkht Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhongzhu Healthcare Holding Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Lanzhou Foci Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Shandong Himile Mechanical Co., Ltd.
2 interpretationsHigh Retained Earnings With Profitability And EquityIndustry-Benchmarked Return on Capital Elevated
Tong Yang Industry Co., Ltd.
2 interpretationsHigh Retained Earnings With Profitability And EquityRetained Earnings Heavy With Elevated Payout
Allied Supreme Corporation
2 interpretationsHigh Retained Earnings With Profitability And EquityRetained Earnings Heavy With Elevated Payout